Dyne Therapeutics Inc (DYN) Stock Price, Quote & News

Company Profile

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therap...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 786 8230

Fax: 781 786 8866

Website: www.dyne-tx.com

Address:

1560 Trapelo Road, Waltham, United States

Jewstock Aug. 25 at 4:18 PM

$DYN bought 17.5c 3/20/26

0 · Reply

Ohzipit Aug. 25 at 3:11 PM

$DYN see below!

0 · Reply

JarvisFlow Aug. 25 at 2:48 PM

Raymond James has updated their rating for Dyne Therapeutics ( $DYN ) to Strong Buy with a price target of 35.

0 · Reply

Sam201 Aug. 25 at 2:14 PM

$DYN told you all to load. Sold some more now. Rest above 18 ish!

1 · Reply

Jewstock Aug. 25 at 1:58 PM

$DYN anyone buying calls here?

0 · Reply

Jewstock Aug. 25 at 1:48 PM

$DYN go dyn!

0 · Reply

Ohzipit Aug. 25 at 1:13 PM

$DYN RJ upgrade to strong buy increases price target to $35 base case and $65 Bull case.

0 · Reply

ManosDeDiamante07 Aug. 18 at 2:55 PM

$DYN Always winning 😎💰

0 · Reply

MarianoItaliano Aug. 14 at 9:55 AM

Crazy that $DYN has similar market cap to $SRPT. It shows how undervalued Sarepta is

0 · Reply

Jewstock Aug. 13 at 2:11 PM

$DYN oh shit

0 · Reply

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)

Jul 29, 2025, 12:51 PM EDT - 27 days ago

These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss

Jul 28, 2025, 4:10 PM EDT - 27 days ago

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 16, 2025, 7:00 AM EDT - 5 weeks ago

Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

Jul 2, 2025, 4:01 PM EDT - 7 weeks ago

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jul 1, 2025, 9:00 AM EDT - 7 weeks ago

Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

PRGS TSLA

Jun 30, 2025, 9:45 PM EDT - 7 weeks ago

Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

Jun 30, 2025, 4:05 PM EDT - 7 weeks ago

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Jun 30, 2025, 4:01 PM EDT - 7 weeks ago

Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

Jun 24, 2025, 3:43 AM EDT - 2 months ago

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYN

Jun 18, 2025, 11:08 AM EDT - 2 months ago

Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade

Jun 17, 2025, 1:35 PM EDT - 2 months ago

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN

Jun 17, 2025, 7:00 AM EDT - 2 months ago

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

Jun 16, 2025, 4:05 PM EDT - 2 months ago

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET

Jun 5, 2025, 7:30 AM EDT - 2 months ago

Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress

May 8, 2025, 7:30 AM EDT - 3 months ago

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 24, 2025, 7:30 AM EDT - 4 months ago

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

Apr 15, 2025, 7:30 AM EDT - 4 months ago

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

Apr 14, 2025, 4:30 PM EDT - 4 months ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 20, 2025, 4:30 PM EDT - 5 months ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

Mar 20, 2025, 4:10 PM EDT - 5 months ago

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

Mar 16, 2025, 7:00 PM EDT - 5 months ago

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Mar 13, 2025, 9:09 AM EDT - 5 months ago

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Mar 12, 2025, 3:05 PM EDT - 5 months ago

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

Mar 11, 2025, 7:30 AM EDT - 5 months ago

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

Feb 27, 2025, 7:30 AM EST - 6 months ago

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 14, 2025, 4:05 PM EST - 6 months ago

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

Feb 3, 2025, 7:30 AM EST - 7 months ago

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 21, 2025, 7:30 AM EST - 7 months ago

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Jan 10, 2025, 1:40 PM EST - 8 months ago

Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

Jan 10, 2025, 6:30 AM EST - 8 months ago

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

Jan 9, 2025, 7:30 AM EST - 8 months ago

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 8 months ago

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

Nov 11, 2024, 6:15 PM EST - 10 months ago

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

Nov 7, 2024, 4:15 PM EST - 10 months ago

Dyne Therapeutics to Present at Upcoming Investor Conferences

Nov 3, 2024, 11:00 AM EST - 10 months ago

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Oct 31, 2024, 11:00 AM EDT - 10 months ago

Dyne Therapeutics Inc Is Being Sued For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Oct 29, 2024, 11:00 AM EDT - 10 months ago

Dyne Therapeutics Inc May Have Committed Securities Fraud And Stockholders With Losses Are Urged To Reach Out To The Schall Law Firm

Oct 26, 2024, 11:00 AM EDT - 10 months ago

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Oct 20, 2024, 11:00 AM EDT - 11 months ago

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Urged To Contact The Schall Law Firm

$The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Related Infractions$

Oct 17, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Related Infractions

Jewstock Aug. 25 at 4:18 PM

$DYN bought 17.5c 3/20/26

0 · Reply

Ohzipit Aug. 25 at 3:11 PM

$DYN see below!

0 · Reply

JarvisFlow Aug. 25 at 2:48 PM

Raymond James has updated their rating for Dyne Therapeutics ( $DYN ) to Strong Buy with a price target of 35.

0 · Reply

Sam201 Aug. 25 at 2:14 PM

$DYN told you all to load. Sold some more now. Rest above 18 ish!

1 · Reply

Jewstock Aug. 25 at 1:58 PM

$DYN anyone buying calls here?

0 · Reply

Jewstock Aug. 25 at 1:48 PM

$DYN go dyn!

0 · Reply

Ohzipit Aug. 25 at 1:13 PM

$DYN RJ upgrade to strong buy increases price target to $35 base case and $65 Bull case.

0 · Reply

ManosDeDiamante07 Aug. 18 at 2:55 PM

$DYN Always winning 😎💰

0 · Reply

MarianoItaliano Aug. 14 at 9:55 AM

Crazy that $DYN has similar market cap to $SRPT. It shows how undervalued Sarepta is

0 · Reply

Jewstock Aug. 13 at 2:11 PM

$DYN oh shit

0 · Reply

ManosDeDiamante07 Aug. 10 at 10:19 PM

$DYN

0 · Reply

Syncor Aug. 10 at 2:35 PM

$DYN https://firstwordpharma.com/story/5814780#:~:text=DYNE%2D251%20increased%20dystrophin%20protein,in%20the%20confirmatory%20PROMOVI%20study.

0 · Reply

Syncor Aug. 9 at 3:37 AM

$DYN seems like a Sarepta part 2 company…not sure if you guys research the employees on linkedin but seems like all were from sarepta…btw, I don’t mean this in a good way…good luck searching for your pot of gold….…..question to your board…for a company with no revenue why do you have so many employees….many overlaps…curious what they do all day

1 · Reply